Mazdutide

A dual GLP-1 and glucagon receptor agonist showing strong weight loss data, particularly in Asian population clinical trials.

An oxyntomodulin analogue activating both GLP-1 and glucagon receptors, combining appetite suppression with increased energy expenditure.

Mazdutide is built on oxyntomodulin, a natural gut hormone that hits two receptors at once. Trials in Asian populations have shown strong weight and metabolic results.

• Percentage body weight reduction
• HbA1c change
• Waist circumference
• Liver fat fraction
• Lipid markers

• Obesity GLORY trial programme
• Type 2 diabetes glycaemic endpoints
• Metabolic markers in Asian populations
• Hepatic fat reduction

Licensed from Eli Lilly and developed by Innovent Biologics in China, where it has advanced through large Phase 3 obesity and diabetes trials.

Men and women 30-65 focused on weight loss and metabolic health.

• Reconstitute with sterile or bacteriostatic water.
• Add diluent slowly and swirl gently.
• Weekly protocol modelling based on extended half-life.
• Store lyophilised at -20C, reconstituted at 2-8C.
• Protect from light and avoid freeze-thaw.

• Primary trial data comes from Asian population cohorts.
• Glucagon component increases energy expenditure.
• Dose escalation matters for GI tolerability.
• Comparative Western data is still limited.